Antiviral L-nucleosides specific for hepatitis B virus infection

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 1, 2001, Pages 229-235

  Bryant, M L ^a   Bridges, E G ^a   Placidi, L ^a   Faraj, A ^a   Loi, A G ^a   Pierra, C ^a   Dukhan, D ^a   Gosselin, G ^a   Imbach, J L ^a   Hernandez, B ^a   Juodawlkis, A ^a   Tennant, B ^a   Korba, B ^a   Cote, P ^a   Marion, P ^a   Cretton Scott, E ^a   Schinazi, R F ^a   Sommadossi, J P ^a  

^a Novirio Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2' DEOXYNUCLEOSIDE; DEOXYADENOSINE; DEOXYCYTIDINE; NUCLEOSIDE DERIVATIVE; THYMIDINE DERIVATIVE;

ANTIVIRAL ACTIVITY; ARTICLE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; VIRUS LOAD; VIRUS REPLICATION;

ANIMALS; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; BONE MARROW CELLS; CELL LINE; DEOXYADENOSINES; DEOXYCYTIDINE; DNA, VIRAL; DNA-DIRECTED DNA POLYMERASE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HIV-1; HUMANS; MALE; MARMOTA; NUCLEOSIDES; STEM CELLS; THYMIDINE; VIRUS REPLICATION;

EID: 0035172399     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.1.229-235.2001     Document Type: Article

References (55)

1. Multiple drug effect analysis with confidence interval
2. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine
3. Anti-human immunodeficiency and anti-hepatitis B virus activities of beta-L-2′,3′-dideoxy purine nucleosides
4. Deoxycytidine deaminase-resistant stereoisomer is the active form of (+/-)-2′,3′-dideoxy-3′-thiacytidine in the inhibition of hepatitis B virus replication
5. Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2′,3′-dideoxycytidine
6. Use of 2′-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus
7. New enzyme immunoassays for the serologic detection of woodchuck hepatitis virus infection
8. Effect of 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil on mitochondrial functions in HepG2 cells
9. Mitochondrial DNA effect of nucleoside analogs on neurite regeneration and mitochondrial DNA synthesis in PC-12 cells
10. Effect of β-enantiomeric and racemic nucleoside analogues on mitochondrial functions in HepG2 cells
11. Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-β-D-arabinofuranosyl)-5-iodouracil in human liver cells
12. Mitochondrial myopathy caused by long-term zidovudine therapy
13. Interferon treatment of viral hepatitis in immunocompromised patients
14. Lamivudine as initial treatment for chronic hepatitis B in the United States
15. Effects of 2′,3′-dideoxynucleosides on proliferation and differentiation of human pluripotent progenitors in liquid culture and their effects on mitochondrial DNA synthesis
16. Inhibition of human immunodeficiency virus type 1 reverse transcriptase by the 5′-triphosphate beta enantiomers of cytidine analogs
17. Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection
18. Stereospecificity of human DNA polymerases alpha, beta, gamma, delta and epsilon, HIV-reverse transcriptase, HSV-1 DNA polymerase, calf thymus terminal transferase and Escherichia coli DNA polymerase I in recognizing D- and L-thymidine 5′-triphosphate as substrate
19. The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoru-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
20. Efficacy of the carbocyclic 2′-deoxyguanosine nucleoside BMS-200475 in the woodchuck model of hepatitis B virus infection
21. New unnatural L-nucleoside enantiomers: From their stereoselective synthesis to their biological activities
22. Enantiomeric 2′,3′-dideoxycytidine derivatives are potent human immunodeficiency virus inhibitors in cell culture
23. From D- to L-nucleoside analogs as antiviral agents
24. The treatment of chronic viral hepatitis
25. Stavudine: An update of its use in the treatment of HIV infection
26. Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication
27. A one-year trial of lamivudine for chronic hepatitis B
28. Zidovudine induces molecular, biochemical, and ultrastructural changes in rat skeletal muscle mitochondria
29. Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts
30. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
31. Effect of stereoisomerism on the cellular pharmacology of beta-enantiomers of cytidine analogs in Hep-G2 cells
32. Lamivudine therapy of WHV-infected woodchucks
33. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B
34. Transgenic mice as a chemotherapeutic model for hepatitis B virus infection
35. Differential effects of antiretroviral nucleoside analogs on mitochondrial function in HepG2 cells
36. Intracellular metabolism of β-L-2′,3′-dideoxyadenosine: Relevance to its limited antiviral activity
37. Pharmacokinetics of (-)-2′-3′-dideoxy-3′-thiacytidine in woodchucks
38. Fialuridine accumulates in DNA of dogs, monkeys, and rats following long-term oral administration
39. Pure nucleoside enantiomers of beta-2′,3′-dideoxycytidine analogs are selective inhibitors of hepatitis B virus in vitro
40. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine
41. Activities of 3′-azido-3′deoxythymidine nucleotide dimers in primary lymphocytes infected with human immunodeficiency virus type 1
42. Stereoisomers of deoxynucleoside 5′-triphosphates as substrates for template-dependent and -independent DNA polymerases
43. Synthesis and biological evaluation of 2′,3′-didehydro-2′,3′- dideoxy-5-fluorocytidine (D4FC) analogues: Discovery of carbocyclic nucleoside triphosphates with potent inhibitory activity against HIV-1 reverse transcriptase
44. Uridine reverses the toxicity of 3′-azido-3′-deoxythymidine in normal human granulocyte-macrophage progenitor cells in vitro without impairment of antiretroviral activity
45. Cellular pharmacology of 3′-azido-3′-deoxythymidine with evidence of incorporation into DNA of human bone marrow cells
46. L-Thymidine is phosphorylated by herpes simplex virus type 1 thymidine kinase and inhibits viral growth
47. Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection
48. The woodchuck in preclinical assessment of therapy for hepatitis B virus infection
49. The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: A phase I study
50. Lack of enantiospecificity of human 2′-deoxycytidine kinase: Relevance for the activation of beta-L-deoxycytidine analogs as antineoplastic and antiviral agents
51. Recent advances in L-nucleosides: Chemistry and biology
52. Zalcitabine. A review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS)
53. Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy
54. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis